This is the peer reviewed version of the following article:

Gogoi Tiwari, J. and Babra Waryah, C. and Sunagar, R. and Veeresh, H. and Nuthanalakshmi, V. and Preethirani, P. and Sharada, R. et al. 2015. Typing of Staphylococcus aureus isolated from bovine mastitis cases in Australia and India. Australian Veterinary Journal. 93 (8): pp. 278-282.,

which has been published in final form at http://doi.org/10.1111/avj.12349

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving at http://olabout.wiley.com/WileyCDA/Section/id-820227.html#terms

1 **Typing of *Staphylococcus aureus* isolated from bovine mastitis cases in Australia and**
2 **India**

3 J Gogoi-Tiwari[a], C Babra Waryah[a], R Sunagar[c], HB Veeresh[d], V Nuthanalakshmi[d], PL
4 Preethirani[d], R Sharada[d], S Isloor[d], Avinash Bhat[d], H Al-Salami[b], NR Hegde[c] and TK
5 Mukkur[*a]

6

7 [a]Schools of Biomedical Sciences and Pharmacy[b], Faculty of Health Sciences, Curtin Health
8 Innovation Research Institute, CHIRI Biosciences Research Precinct, Curtin University,
9 Bentley, Perth, Western Australia 6102 Australia

10 [c]Ella Foundation, Genome Valley, Shameerpet Mandal, Hyderabad 500 078, India

11 [d]Veterinary College, Karnataka Veterinary, Animal and Fisheries Sciences University,
12 Hebbal, Bangalore 560024, India

13

14 *[a] Corresponding author: School of Biomedical Sciences, Faculty of Health Sciences, Curtin
15 University, Perth 7102 Western Australia, Australia. Phone: +61 8 9266 7520. Facsimile: +61
16 8 9266 2342; Email: T.Mukkur@curtin.edu.au

17
18
19
20
21
22
23
24
25
26
27
28

Abstract

Objective To determine the prevalence of the different capsular polysaccharide (CP) and the major surface-associated non-CP antigen 336 (SP-336) types among *S. aureus* isolated from bovine mastitis cases in Australia and India.

Methods A total of 414 strains (154 from Australia and 260 from India) isolated from clinical bovine mastitis were included for the study. Mouse antisera raised against CP types (CP1, CP2, CP5, and CP8) or SP-336 were used in slide agglutination tests and compared to detection of *cap*1, *cap*5 and *cap*8 gene fragments by PCR.

Results Serological studies revealed the presence of CP2, CP5, CP8 and SP-336 in 9.1%, 23.4%, 31.8%, and 5.8% of the Australian versus 0.8%, 46.9%, 13.1% and 0% of the Indian isolates, respectively. By PCR, CP1, CP5 and CP8 accounted for 0%, 26.6% and 32.4% of the Australian versus 3.9%, 85% and 8.1% of the Indian isolates, respectively.

Conclusions Both PCR and serological study have demonstrated that CP5 and CP8 are the predominant capsular types in Australia whereas CP5 is the predominant capsular type in India. The study has also demonstrated a strong correlation between both the methods of typing for CP1, CP5, CP8 and non-typeable *S. aureus* strains. Prevalence of high percentages of non-typeable isolates in both the countries highlights the importance of continued investigations on the identification of unique surface-associated polysaccharide antigens prevalent among *S. aureus* isolates for the formulation of CP and SP-based vaccines for bovine mastitis.

Key words capsular and polysaccharide antigen 336, dairy cattle, mastitis, serology, molecular typing

Abbreviations CP, Capsular polysaccharide; SP, Surface polysaccharide; PCR, Polymerase chain reaction; MSSA, Methicillin sensitive *Staphylococcus aureus*; AISRF, Australia India

54 Strategic Research Fund; MH, Mueller Hinton; ATCC, American type culture collection;
55 CFU, Colony forming unit; DNA, Deoxyribonucleic acid; UV, Ultra violet; PNAG, Poly-N-
56 acetyl glucosamine; CHIRI, Curtin Health Innovation Research Institute.

57

58 Introduction

59 The Australian and Indian dairy industries sustain economic losses estimated to be more
60 than US$130 million[1] and US$1200 million[2], respectively, due to poor udder health, which is
61 mainly caused by mastitis. *Staphylococcus aureus* is one of the predominant causative agents
62 of clinical mastitis in most countries[3-7] including India[2,8] and Australia.[9] The current
63 conservative practice of treating mastitis with antibiotics is not only economically unviable in
64 the long term, especially for the marginal and small-scale dairy farmers in India, but also
65 promotes the emergence of strains resistant to antibiotics including methicillin.[10-15] Given the
66 recent reports that even MSSA (methicillin-sensitive *Staphylococcus aureus*) can become
67 resistant to certain antimicrobials when presented as biofilms adds another dimension to
68 bovine mastitis caused even by MSSA.[16-18] In addition, there is increasing evidence for cross
69 transmission of virulent *S. aureus* between dairy cattle and humans[19-23] with implications for
70 public health. There is an urgent need for a suitable vaccine against mastitis to reduce the
71 bacterial load and the probability of successful cross transmission.

72

73 Capsular polysaccharide (CP) is one of the most important virulence factors of *S. aureus*[24,25]
74 as it confers resistance to phagocytosis[26] and prolongs persistence of the pathogen in the
75 blood stream of the host.[27] Earlier serological studies suggested the existence of 11 different
76 serotypes of CP.[28,29] However, a more recent study[30] indicated that there were only four types
77 (CP 1, 2, 5 and 8), all the other reported types representing mutated versions. Most human
78 clinical isolates have been reported to express either CP5 or CP8, accounting for ~80% of the

79 total isolates from all sources.[31,26] The rest were designated non-typeable *S. aureus*; most of
80 these strains were reported to possess a unique surface polysaccharide antigen 336[29], which
81 contained polyribitol-phosphate-*N*-acetylglucosamine, a component of cell wall teichoic
82 acid.[26]

83

84 Knowledge of the type of CPs of the *S. sureus* isolates circulating on farms is essential in the
85 formulation of the CP-based conjugate vaccine formulations because of their better
86 immunogencity due to T cell-dependence than the capsular polysaccharide formulations
87 which are T cell-independent[32-34]. Since the prevalence of CPs may be different in different
88 countries[28,31,35-38], conjugate vaccine formulations specific for each farm or a broad-spectrum
89 vaccine representing all the capsular types, surface-associated immune evasion molecules[39],
90 conjugated to the most significant homologous or heterologous colonisation protein
91 antigen(s), may be need to be formulated.

92 Because of the distribution of the different capsular types of *S. aureus* around the world may
93 differ[35-38], it is important to know their prevalence in Australia and India used in this study as
94 model developing country with backyard farming practices, in order to rationally select
95 suitable vaccine candidates as vaccine candidates. However, there are no reports on the
96 prevalence of different CP types of *S. aureus* causing bovine mastitis either in Australia or in
97 India. Hence the objective of this study was to determine the distribution of different capsular
98 phenotypes among the Australian and the Indian *S. aureus* strains isolated from clinical
99 bovine mastitis cases.

100

101 **Material and Methods**

102 ***S. aureus isolates***

103 One hundred and fifty four (154) fully characterised *S. aureus* strains of Australian origin
104 isolated from clinical cases of mastitis in cows in Victoria and Queensland were generously
105 donated by Professor Margaret Deighton, (RMIT University), Dr. Sharon de Wet
106 (Queensland Biosecurity laboratory) and Dr. Justine Gibson (University of Queensland). In
107 India, 260 strains were isolated from clinical cases of mastitis in cows from different parts of
108 the country (Karnataka, Andhra Pradesh, Goa, Uttar Pradesh and Gujarat) and identified as
109 *S. aureus* using the standard biochemical tests.[40] Reference strains representing CP types 1
110 (strain M), 2 (strain Smith diffuse), 5 (strain Newman), 8 (USA 400 MW2) and a non-
111 capsulated strain (LAC, USA 300) were donated by Professor Gerald Pier (Harvard Medical
112 School, Boston, USA). *S. aureus* ATCC-55804 designated as serotype 336 was purchased
113 from ATCC, USA. These isolates were grown on Mueller Hinton (MH) agar and subcultured
114 in nutrient broth supplemented with 1% glucose and stored on cryobeads (Blackaby
115 Diagnostics) or as glycerol (15%) broth stocks at -80°C.

116

117 ***Production of antisera for serological typing***

118 Six week-old specific pathogen-free Quackenbush Swiss line 5 mice obtained from the
119 Animal Resources Centre, Perth, Western Australia were and used for production of CP and
120 antigen 336-specific antisera. All animal experiments were carried out with the approval of
121 Curtin University's Animal Ethics Committee.

122

123 Preparation of the different anti-CP type 1, 2, 5, 8 and SP-336 antisera was carried out
124 according to Fournier et al. (1984)[41]. Briefly, bacterial suspensions of *S. aureus* CP types-1,
125 2, 5, 8 and SP-336 grown for 18 h on MH agar plated at 37°C and killed with 3%
126 formalinised PBS followed by washing with PBS (5X). Mice were immunized every week
127 for 5 weeks with formalin-killed *S. aureus*. The first three doses containing the equivalent to

128 $5x10^7$, $1x10^8$ and $5x10^8$ CFU in 0.2mL respectively, were administered by the intraperitoneal
129 route.. For the fourth and fifth doses, the bacterin was mixed with equal proportion with
130 Imject Alum (Thermo Scientific) and 0.2 mL containing an equivalent of $1x10^9$ and $5x10^9$
131 CFU, respectively, and administered subcutaneously one week apart. Mice were blood
132 samples for collection of sera. The CP-/SP-specific antisera were cross-absorbed with non-
133 capsulated *S. aureus* strain LAC, USA 300, followed by cross-absorption with the
134 heterologous CP types CP1, CP2, CP5, and CP8 depending upon the desired CP specificity.
135 For SP-336 serum, the same method was followed, initially cross absorbed with non-
136 capsulated LAC USA followed by cross absorption with CP 1, 2 5 and 8.

137

138 ***CP serotyping of S. aureus isolates***

139 Slide agglutination test was performed to determine the serotype of the strains.[26] Each strain
140 was grown overnight on MH agar and a single colony was resuspended in a drop of 0.9%
141 normal saline in a clean glass slide. A drop of serum was added to it and observed for
142 agglutination in less than 20 sec. The strains, which showed no agglutination against any of
143 the four sera, were further tested for agglutination using anti-SP336 serum. Strains found
144 negative with all the five specific sera were considered as non-typeable.

145

146 ***CP genotyping of S. aureus isolates***

147 Genomic DNA was extracted from *S. aureus* using a kit (Geneworks, SA, Aust or Real
148 Biotech Corp., Taiwan) Detection of the presence of *cap*1, *cap*2, *cap*5 and *cap*8 loci in all the
149 strains was done by Polymerase Chain Reaction (PCR). The primers used for typing *cap*1 are
150 5'-AGG TCT GCT AAT TAG TGC AA-3' (forward) and 5'-GAA CCC AGT ACA GGT
151 ATC ACC A-3' (reverse) with an expected product size of 550 bp and for *cap*2 are 5'-AGC
152 AAT CTT CGG TTA TTG CCG GTG-3' (forward) and 5'-ATG ACG GTA AGG CAT

153 CAA GGT CG-3' (reverse) with an expected amplicon size (non-specific). The PCR cycling
154 parameters for both *cap*1 and *cap*2 were: denaturation at 94°C for 5 min followed by 94°C for
155 30 sec, Tm at 57°C (*cap*1) or 60°C (*cap*2) for 30 sec, 72°C for 60 sec with 25-30 cycles and
156 final extension at 72°C for 5 min.

157

158 The primers used for typing *cap*5 and *cap*8 were 5'- ATG ACG ATG AGG ATA GCG-3'
159 (forward) and 5'- CTC GGA TAA CAC CTG TTG C-3' (reverse) for *cap*5 and 5'- ATG
160 ACG ATG AGG ATA GCG-3' (forward) and 5'- CAC CTA ACA TAA GGC AAG-3'
161 (reverse) for *cap*8, respectively.[42] The expected band sizes were 881 bp and 1148 bp for *cap*5
162 and *cap*8, respectively. Thermal cycling conditions were denaturation at 95°C for 5 min,
163 95°C for 30 sec, Tm of 55°C (*cap*5) or 52°C (*cap*8) for 30 sec, 72°C for 5 min with 25-30
164 cycles and the final extension at 72°C for 5 min.

165

166 The PCR products were analysed by agarose gel (1.5%) electrophoresis, Midori Green
167 staining and UV trans-illumination. The positive controls included strains M, Smith Diffuse,
168 Newman and USA 400 for *cap*1, *cap*2, *cap*5 and *cap*8, respectively, and LAC, USA 300 was
169 used as negative control.

170

171 ***Statistical analysis***

172 Correlation coefficients, represented as Pearson *r* values, between the serological with the
173 genotyping method, for CP1, CP5, CP8 positive and non-typeable *S. aureus* strains, were
174 determined using Microsoft Excel, Windows 10.

175

176 **Results**

177 ***Prevalence of capsular or antigen 336 types in bovine S. aureus isolates***

178 Genotyping of 154 Australian *S. aureus* isolates revealed that 41 (26.62%) and 50 (32.47%)
179 strains were positive for *cap*5 and *cap*8 (Table1). None of the isolates were positive for the
180 *cap*1 locus. The primers for the *cap*2 locus exhibited cross-reactivity with all the other three
181 CP types producing amplicons of 700-800 bp (data not shown). A total of 63 (40.91%) *S.*
182 *aureus* strains, which carried none of the three loci (*cap*5, *cap*8 or *cap*1), were declared as
183 negative by PCR (Table1).

184

185 Serotyping of 154 *S. aureus* isolates using CP-specific sera (Table 1) confirmed the
186 genotyping results; 36 (23.4%) and 49 (31.8%) of the isolates revealed the presence of CP5
187 and CP8, respectively, whereas none was positive for CP1. However, 14 (9.1%) strains were
188 positive for CP2. The strains that were not agglutinated by any of the CP-specific sera were
189 subjected to slide agglutination using anti-SP336 antiserum. Nine (5.8%) isolates were
190 positive for SP-336 and the remaining 46 (29.9%) were declared as non-typeable.

191

192 Among the 260 Indian isolates, 10 (3.9%), 221 (85%) and 21(8.1%) were positive for *cap*1,
193 *cap*5 and *cap*8 loci, whereas the 8 (3.08%) negative for all the three loci were considered as
194 non-capsulated in genotyping. Serotyping revealed that 2 (0.8%), 122 (46.9%) and 34
195 (13.1%) isolates were positive for CP1, CP5 and CP8, respectively. None of the remaining
196 isolates was positive for either CP2 or SP-336, indicating that 102 (39.2%) isolates were non-
197 typeable (Table 1).

198

199 The correlation coefficient (r) between the serological and genotyping methods for detection
200 of CP types 1, 5 and 8, and the non-typeable *S. aureus* isolates, was determined to be 0.97
201 and 0.66 for Australian and Indian *S. aureus* isolates, respectively

202

203 **Discussion and conclusions**

204 Given the role of surface-associated polysaccharides in the virulence of *S. aureus*,
205 epidemiological investigations on the distribution of capsular and surface polysaccharide
206 types among *S. aureus* isolates is important for rational design of a vaccine formulation
207 against infection with *S. aureus*. Studies on human *S. aureus* capsular types have reported
208 that 75-80% of all the isolates produce either CP5 or CP8.[38,43,44] However, the prevalence of
209 the CP serotypes (CP5 and 8) among the *S. aureus* strains isolated from cow's milk ranges
210 from as low as 14% to as high as 95%.[29,31,45,46] Others[47] reported that CP typing was superior
211 to bacteriophage typing whereas another study[48] had reported the capsular typing was less
212 sensitive than genome typing yielding 26 different *S. aureus* types. Another study analyzed
213 the genetic diversity of *S. aureus* isolated from subclinical mastitis cases in cows and
214 reported the presence of 16 types and 24 subtypes[46]. However, no information on their
215 correlation with the different capsular types was reported.
216
217 The present study revealed that 64.3% of Australian bovine mastitis-associated *S. aureus*
218 strains expressed capsule, of which, CP8 was predominant (31.8%), followed closely by CP5
219 (23.4%). A total of 60.8% of the Indian isolates expressed capsule, of which CP5 type was
220 dominant (46.9%). In addition, 5.8% (nine of 154) of the Australian isolates were positive for
221 SP-336, whereas none of the Indian isolates were positive for this antigen. The fact that about
222 40% of the Indian isolates were non-typeable suggests the possible existence of more diverse
223 *S. aureus* populations in India than in Australia where about 30% of the isolates were non-
224 typeable. These differences could be due to a multitude of factors including breed, husbandry
225 and therapeutic practices, human-animal interface and various other environmental factors
226 that are different between the two countries. However, it is difficult to draw any conclusions
227 on whether *S. aureus* is transmitted between humans and animals in India because of a wide

228 variation in the distribution of the capsular phenotypes ranging from 21% to 63% for CP5
229 and 37% to 64% for CP8[47,49,50]. There are no publications on the distribution of CP types of
230 bovine mastitis-associated *S. aureus* isolates from Australia, although only one study has
231 genotypically characterised the CP5 and CP8 of Indian isolates[51]. That study revealed that
232 60% of the cattle isolates and 20% of the goat isolates carried the *cap*5 gene, and 20% and
233 30% of cattle and goat isolates, respectively, carried the *cap*8 gene.[51] However, only 20 *S.*
234 *aureus* isolates were used in that study whereas 260 isolates from different parts of India
235 were used in this study, projecting a more reliable distribution of CP types in India.

236

237 Very few studies have compared the performance of genotyping versus serology in the typing
238 of *S. aureus* isolates. One study compared the prevalence of CP5 and CP8 types of
239 *Staphylococcus aureus* among isolates from intramammary infections in Argentine dairy
240 cattle and found 64% of the isolates as genotypes *cap*5 or *cap*8 and 50% as CP5 or 8
241 serologically[52]. In contrast, one study with human isolates, there was 100% correlation
242 between capsular genotypes and phenotypes for CP5 and CP8.[53] In this study, five (3.3%)
243 Australian bovine mastitis-associated strains carrying *cap*5 and one strain (0.7%) carrying
244 *cap*8 were negative by agglutination. More strikingly, 99 (38.1%) *cap*5 positive and eight
245 (3.1%) *cap*1 positive Indian *S. aureus* strains did not express respective capsular phenotype
246 when judged by serological typing. In contrast, 13 (5%) Indian strains that were positive for
247 CP8 by serology were negative by genotyping. The discordance between genotyping and
248 phenotyping may be attributable to non-expression of respective capsule-encoding genes,
249 possibly due to mutations[30] or due to the difference in culture conditions *in vivo* and *in*
250 *vitro*.[54,55]

251

252 It is thus clear from this study that any surface-associated polysaccharide antigens-based
253 vaccine formulation should not only include CP5 and CP8 types but also other capsular types,
254 with or without antigen 336 or poly-N-acetyl glucosamine (PNAG), reported to be present in
255 all *S. aureus* isolates[56] for prevention of clinical bovine mastitis caused by *S. aureus*. The
256 prevalence of 29.87% and 39.23% of non-typeable *S. aureus* strains in Australia and India,
257 respectively, also highlights the need to explore the existence of other surface-associated
258 polysaccharides including additional capsular phenotypes as proposed originally.[43]
259

260 **Acknowledgements**

261 The work was supported by grants through the Australia India Strategic Research Fund
262 [BF040038] from the Department of Innovation, Industry, Science and Research,
263 Commonwealth Government of Australia (to TKM), and the India-Australia Biotechnology
264 Fund [BT/Indo-Aus./04/06/2009] from the Department of Biotechnology, Ministry of
265 Science and Technology, Government of India (to NRH and SI). Thanks are also due to
266 Curtin University for providing the International Postgraduate Research Scholarship and the
267 Australian Postgraduate Award to JG-T in support her doctoral studies. The authors
268 acknowledge the provision of research facilities and the scientific and technical assistance of
269 the staff of CHIRI Biosciences Research Precinct Core Facility, Curtin University. The
270 authors are also grateful to Gerard Pier, Harvard University, for providing isolates expressing
271 specific capsular polysaccharides.
272

273 **Conflict of interest**

274 The authors declare that they have no conflict of interests.

275

276 **References**

277 1. Dairy Australia (2011). Dairy Australia Strategic Plan 2011-2015.
278 http://www.dairyaustralia.com.au/Our-Dairy
279 Industry/~/media/Publications/Strategic%20Plan/2011%20-
280 %2015/Dairy%20Australias%20strategic%20plans%20for%202011%202015.ashx?la=en
281 . 2011. Retrieved 1st Oct 2011.
282 2. Dua K. Incidence, aetiology and estimated loss due to mastitis in India-An update. Ind
283 Dairy man 2001; 53: 41-48.
284 3. Workineh S, Bayleyegn H, Mekonnen H *et al*. Prevalence and aetiology of mastitis in
285 cows from two major Ethiopian dairies. Trop Anim Health Prod 2002; 34:19-25.
286 4. Barrett DJ, Healy AM, Leonard FC *et al*. Prevalence of pathogens causing subclinical
287 mastitis in 15 dairy herds in the Republic of Ireland. Irish Vet J 2005; 58: 333-337.
288 5. Middleton JR. *Staphylococcus aureus* antigen and challenges in vaccine development.
289 Expert Rev Vaccines 2008; 7: 805-818.
290 6. Unnerstad HA, Lindberg KP, Waller T *et al.* Microbial aetiology of acute clinical
291 mastitis and agent-specific risk factors. Vet Microbiol 2009; 137: 90-97.
292 7. Pereira UP, Oliveira DG, Mesquita LR *et al*. Efficacy of *Staphylococcus aureus*
293 vaccines for bovine mastitis: a systematic review. Vet Microbiol 2011; 148:117-124.
294 8. Sharma N, Maiti SK. Incidence, etiology and antibiogram of sub clinical mastitis in
295 cows in durg, Chhattisgarh. Ind J Vet Res 2010; 19: 45-54.
296 9. Mein GA. Review and recommendations on mastitis issues in the Victorian dairy
297 industry. A review for the Gardiner Foundation. Pp 1-33. 2011.
298 10. Shi D, Hao Y, Zhang A *et al*. Antimicrobial resistance of *Staphylococcus aureus*
299 isolated from bovine mastitis in China. Trans Emerg Dis 2010; 57: 221-224.

300 11. Holmes MA, Zadoks RN. Methicillin resistant *Staphylococcus aureus* in human and
301 bovine mastitis. J Mammary Gland Biol Neoplasia 2011; 16: 373-382.
302 12. Park YK, Fox LK, Hancock DD *et al.* Prevalence and antibiotic resistance of mastitis
303 pathogens isolated from dairy herds transitioning to organic management. Vet Sci
304 2012; 13: 103-105.
305 13. Haran KP, Godden SM, Boxrud D *et al*. Prevalence and characterization of
306 *Staphylococcus aureus*, including methicillin resistant *Staphylococcus aureus* isolated
307 from bulk tank milk from Minnesota dairy farms. J Clin Microbiol 2012; 50: 688-695.
308 14. Paterson GK, Harrison EM, Craven EF *et al*. Incidence and characterisation of
309 methicillin resistant *Staphylococcus aureus* (MRSA) from nasal colonization in
310 participants attending a cattle veterinary conference in the UK. PLOS one 2013;
311 http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0068463
312 15. Pu W, Su Y, Li J *et al*. High incidence of oxacillin-susceptible *mecA* positive
313 *Staphylococcus aureus* (OS-MRSA) associated with bovine mastitis in China. PLOS
314 one 2014;
315 http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0088134
316 16. Melchior MB, Vaarkamp H, Fink-Gremmels J. Biofilms: a role in recurrent mastitis
317 infections? Vet J 2006; 171: 398-407.
318 17. Melchior MB, Fink-gremmels J, Gaastra W. Comparative assessment of the
319 antimicrobial susceptibility of *Staphylococcus aureus* isolates from bovine mastitis in
320 biofilm versus planktonic culture. J Vet Med B Infect Dis Vet Public Health 2006;
321 326-332.
322
323

324 18. Babra C, Gogoi-Tiwari J, Pier G *et al.* The persistence of biofilm-associated antibiotic
325 resistance of *Staphylococcus aureus* isolated from clinical bovine mastitis cases in
326 Australia. Folia Microbial 2013. Published online 28th Feb, 2013 (Available online).
327 19. Devriese LA. Coagulase-negative staphylococci in animals. In: Mardh PA, Schleifer
328 KH, editors. *Coagulase negative staphylococci*. Alunguist and Wiksell Int, Stokholm,
329 1986: 51-77.
330 20. Sol J, Sampimon OC, Barkema HW *et al*. Factors associated with cure after therapy
331 of clinical mastitis caused by *Staphylococcus aureus*. J Dairy Sci 2000; 83: 278-284.
332 21. Gogoi-Tiwari J, Tiwari HK. Staphylococcal zoonosis on dairy farms in Assam and
333 Meghalaya. Indian J Pub. Hlth 2007; 51:97-100.
334 22. Sakwinska O, Giddey M, Moreillon M *et al*. *Staphylococcus aureus* host range and
335 human host shift. Appl Environ Microbiol 2011; 77: 5908-5915.
336 23. Fluit AC. Livestock-associated *Staphylococcus aureus*. Clin Microbiol Infect 2012;
337 18: 735-744.
338 24. Wilkinson BJ. Staphylococcal capsules and slime. In: Easmon C, Adlam C, editors.
339 *Staphylococci and staphylococcal infections*. Academic Press, London, 1983: 481-
340 523.
341 25. Thakker M, Park JS, Carey V *et al*. *Staphylococcus aureus* Serotype 5 Capsular
342 polysaccharide is antiphagocytic and enhances bacterial virulence in a murine
343 bacteraemia model. Infect Immun 1998; 66: 5183-5189.
344 26. Verdier I, Durand G, Bes M *et al.* Identification of the capsular polysaccharides in
345 *Staphylococcus aureus* clinical isolates by PCR and agglutination tests. J Clin
346 Microbiol 2007; 45: 725-729.
347 27. O'Riordan K, Lee JC. *Staphylococcus aureus* Capsular Polysaccharides. Clin
348 Microbiol Rev 2004; 17: 218-234.

349 28. Sompolinsky D, Samra Z, Karakawa WW *et al*. Encapsulation and capsular types in
350 isolates of *Staphylococcus aureus* from different sources and relationship to phage
351 types. J Clin Microbiol 1985; 22**:** 828-834.

352 29. Guidry A, Fattom A, Patel A. Serotyping scheme for *Staphylococcus aureus* isolated
353 from cows with mastitis. Am J Vet Res 1998; 59:1537-1539.

354 30. Cocchiaro JL, Gomez MI, Risley A *et al*. Molecular characterization of the capsule
355 locus from non-typeable *Staphylococcus aureus.* Mol Microbiol 2006; 59: 948-960.

356 31. Poutrel B, Boutonnier A, Sutra L *et al*. Prevalence of capsular polysaccharide types 5
357 and 8 among *Staphylococcus aureus* isolates from cow, goat, and ewe milk. J Clin
358 Microbiol 1988; 26: 38-40.

359 32. Fattom AR, Schneerson SS, Vann W *et al*. Synthesis and immunologic properties in
360 mice of vaccines composed of *Staphylococcus aureus* type 5 and type 8 capsular
361 polysaccharides conjugated to *Pseudomonas aeruginosa* exotoxin A. Infect Immun
362 1990; 58: 2367-2374.

363 33. Goldblatt D. Conjugate Vaccines. Clin Exp Immunol 2000; 119:1-3.
364
365 34. Ma J, Cocchiaro J, Lee JC. Evaluation of serotypes of *Staphylococcus aureus* strains
366 used in the production of a bovine mastitis bacterin. J Dairy Sci 2004; 87: 178-182.

367 35. Arbeit RD, Karakawa WW, Vann WF *et al*. Predominance of two newly described
368 capsular polysaccharides types among clinical isolates of *Staphylococcus aureus*.
369 Diagn Microbiol Infect Dis 1984; 2: 85-91.

370 36. Hochkeppel HK, Brun DG, Vischer W, Imm A, Sutra S, Staeunli U *et al*. Serotyping
371 and electron microscopy studies of *Staphylococcus aureus* clinical isolates with
372 monoclonal antibodies to capsular polysaccharide type 5 and type 8. J Clin Microbiol
373 1987; 25:526-30.

374 37. Han HR, Pak SI, Guidry A. Prevalence of capsular polysaccharide (CP) types of
375 Staphylococcus aureus isolated from bovine mastitic milk and protection of
376 *Staphylococcus aureus* infection in mice with CP vaccine. J Vet Med Sci 2000; 62:
377 1331-1333.

378 38. Roghmann M, Taylor KL, Gupte A *et al*. Epidemiology of capsular and surface
379 polysaccharide in *Staphylococcus aureus* infections complicated by bacteraemia.
380 Hosp Infect 2005; 59: 27-32.

381 39. Nanra JS , Buitrago SM,Crawford S *et al*. Capsular polysaccharides are an important
382 immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother
383 2013; 9: 480-487.

384 40. Buchanan RE, Gibbons NE. Bergey's Manual of Determinative Bacteriology.8th ed.
385 Baltimore: The Williams and Wilkins Company, 1974.

386 41. Fournier JM, Bann WF, Karakawa WW. Purification and characterization *of*
387 *Staphylococcus aureus* type 8 capsular polysaccharide. Infect Immun 1984; 45: 87-93.

388 42. Moore PCI, Lindsay JA. Genetic variation among hospital isolates of methicillin-
389 sensitive *Staphylococcus aureus*: Evidence for horizontal transfer of virulence genes.
390 J Clin Microbiol 2001; 39: 2760-2767.

391 43. Karakawa WW, Vann WF. Capsular polysaccharides of *Staphylococcus aureus.*
392 Semin Infect Dis 1982; 4**:** 285-293.

393 44. Lee JC, Liu MJ, Parsonnet J *et al*. Expression of type-8 capsular polysaccharide and
394 production of toxic shock syndrome toxin-1 are associated among vaginal isolates of
395 *Staphylococcus aureus.* J Clin Microbiol 1990; 28*:* 2612-2615.

396 45. Sordelli DO, Buzzola FR, Gomez MI *et al*. Capsule expression by bovine isolates of
397 *Staphylococcus aureus* from Argentina: genetic and epidemiologic analyses. J Clin
398 Microbiol 2000; 38: 846-850.

399 46. Tollersrud T, Kenny K, Caugant DA *et al*. Characterisation of isolates of
400 *Staphylococcus aureus* from acute, chronic and subclinical mastitis in cows in
401 Norway. APMIS 2000; 108**:** 565-572.
402 47. Paul-Satyaseela M, van Belkum A, Shivannavar CT *et al*. Carriage of capsulated
403 strains of *Staphylococcus aureus*: a population-based study performed in Gulbarga,
404 South India. Epidemiol Infect 2004; 132: 831-838.
405 48. Schlichtling L, Branger C, Fournier JM *et al*. Typing of Staphylococcus aureus by
406 pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing:
407 Resolution of clonal relationships. J Clin Microbiol 1993; 31: 227-232.
408 49. Goud R, Gupta S, Neogi U *et al*. Community prevalence of methicillin and
409 vancomycin resistant *Staphylococcus aureus* in and around Bangalore, southern India.
410 Rev Soc Bras Med Trop 2011; 44: 309-312.
411 50. Shambat S, Nadig S, Prabhakara S *et al*. Clonal complexes and virulence factors of
412 *Staphylococcus aureus* from several cities in India. BMC Microbiol 2012; 12: 64.
413 51. Upadhyay A, Kataria AK, Sharma R *et al*. Capsular typing of *Staphylococcus aureus*
414 isolates from cattle and goat mastitis by PCR targeting *cap*5K and *cap*8K genes. Ind J
415 Anim Sci 2010; 80: 1062-1065.
416 52. Camussone C, Rejf P, Pujato N *et al*. Genotypic and phenotypic detection of capsular
417 polysaccharides in *staphylococcus aureus* isolated from bovine intramammary
418 infections in Argentina. Braz J Microbiol 2012; 1010-1014.
419 53. Sutter DE, Summers AM, Keys CE *et al.* Capsule serotype of *Staphylococcus aureus*
420 in the era of community-acquired MRSA. FEMS Immunol Med Microbiol 2011; 63:
421 16-24.

422 54. Poutrel B, Gilbert FB, Lebrun M. Effects of culture conditions on production of type
423 5 capsular polysaccharide by human and bovine *Staphylococcus aureus* strains. Clin
424 Diagn Lab Immunol 1995; 2:166-171.
425 55. Poutrel B, Rainard P, Sarradin P. Heterogeneity of cell associated CP5 expression on
426 *Staphylococcus aureus* strains demonstrated by flow cytometry. Clin Diagn Lab
427 Immunol 1997; 4:275-278.
428 56. Gening ML, Maira-Litran T, Kropec A *et al*. Synthetic β-(1→6)-Linked N-Acetylated
429 and Nonacetylated Oligoglucosamines Used To Produce Conjugate Vaccines for
430 Bacterial Pathogens. Infect Immun 2010; 78: 764–772.

431

432

433

434

435

436

437

438

439

440

441

442

Table 1

Prevalence of capsular/surface polysaccharide phenotypes versus genotypes of *S. aureus* isolates from bovine mastitis cases in Australia and India

Country	No (%) of *S aureus* isolates												
	Total no of isolates	**Detection of capsular type by slide agglutination test (SAT[b])**					**NT[a] by SAT**	**Detection of capsular type by PCR**				**Typing by PCR**	
		CP1	**CP2**	**CP5**	**CP8**	**SP-336**		**CP1**	**CP2**	**CP5**	**CP8**	**SP-336**	**NT[a]**
Australia	154	0 (0)	14 (9.1)	36 (23.4)	49 (31.8)	9 (5.8)	46 (29.9)	0	PDW[c]	41 (26.6)	50 (32.5)	PNA[d]	63 (40.9)
India	260	2 (0.8)	0	122 (46.9)	34 (13.1)	0	102 (39.2)	10 (3.9)	PDW[c]	221 (85)	21 (8.1)	PNA[d]	8 (3.1)

[a]NT= Non-typeable, SAT[b] = Slide agglutination test; [c]PDW= Primers did not work, [d]PNA= Primers not available

Correlation coefficient (*r*) between SAT and PCR method for detection of CP1, CP5,CP8 and non-typeable *S. aureus* strains are 0.97 (Australia) and 0.66 (India).